Podcasts about penn state college

Look around you right now and think for a minute about all of the things you're exposed to: the coffee you're drinking, the mug holding the coffee you're drinking, the soap that mug was washed in, the sleep you got last night -- or didn't get. All of this is part of what we now call your exposome. And as we're learning, the neural exposome influences our risk of developing a range of neurologic diseases.   Our guest today is Dr. Eva Feldman, the  James W Albers Distinguished University Professor and the Russell N. De Young professor of neurology and neurosurgery at the University of Michigan. She'll talk to us about research on the neural exposome in neurodegenerative disease -- and what we should be telling patients and policymakers about this research. Dr. Feldman was interviewed by Dr. Vinita Acharya, Professor of Neurology and Distinguished Educator at Penn State College of Medicine. Guest: Dr. Eva Feldman, the  James W Albers Distinguished University Professor and the Russell N. De Young professor of neurology and neurosurgery at the University of Michigan - https://medicine.umich.edu/dept/mni/eva-feldman-md-phd  Interviewer: Dr. Vinita Acharya, Professor of Neurology and Distinguished Educator at Penn State College of Medicine Disclosures: None

Dare to Disrupt LIVE: Innovating the Future of EV Infrastructure brought together three Penn State alumni at the forefront of the electric vehicle revolution to explore the challenges and opportunities shaping the industry's future. This live episode features an engaging discussion with Benjamin Birnbaum (Keyframe, Terawatt), Zander Isaacson (Xeal), and Diallo Powell (Stak Mobility) as they share insights on EV infrastructure, charging technology, and the role of innovation in accelerating adoption. Whether you're an entrepreneur, investor, or EV enthusiast, this conversation offers a rare opportunity to hear directly from industry leaders driving the future of electric transportation. Benjamin Birnbaum is co-founder and partner at Keyframe, a New York City-based investment firm focused on the energy transition's impact on industry. Prior to Keyframe, he founded Terawatt, an infrastructure developer, owner, and operator for large-scale EV charging. Terawatt has raised over $1 billion and provides fleet charging for companies like Pepsi and Waymo. Ben is a graduate of the Penn State Smeal College of Business. Diallo Powell is co-founder and CEO of Stak Mobility, which addresses urban mobility challenges with an automated vertical carousel system for vehicle storage and EV charging—combining smart software with space-saving infrastructure. Diallo graduated from the Penn State College of the Liberal Arts. Zander Isaacson is co-founder and CEO of Xeal, a technology-first EV charging company at the intersection of proptech, energy, and the Internet of Things. Xeal partners with more than 70 of the largest real estate companies nationwide. Zander, a Penn State Smeal College of Business graduate, is also our first-ever repeat guest on Dare to Disrupt. Together, Ben, Diallo, and Zander discuss the broader trends and challenges shaping the EV landscape, how their companies are uniquely tackling these issues, strategies for scaling and financing capital-intensive projects, and their predictions for the future of the industry. Episode Chapters 0:00 - 7:09 The EV industry landscape at large, building infrastructure 7:09 - 16:35 Fleet vs. consumer charging, offline charging, and urban charging 16:35 - 27:10 Scaling capital-intensive companies 27:10 - 36:38 The future of the EV industry 36:38 - 45:19 Advice for entrepreneurs entering this industry 45:19 - 50:33 Audience questions Dare to Disrupt is made possible by the generous support of the Penn State Smeal College of Business.

Almost everyone needs it, asks for it, gives it, but almost nobody takes it. What is it?Advice. Here's some great advice that's backed by research: Tell your kids some jokes. In this episode of the All Pro Dad Podcast, host Ted Lowe is joined by BJ Foster and Bobby Lewis to talk about how dads who use humor in parenting have better relationships with their kids. Why This MattersA study conducted by Penn State University revealed that people whose parents used humor generally viewed their upbringing positively and tended to have a better relationship with their parents when they became adults. Key TakeawaysHumor Matters: A parent's use of humor directly impacts the quality of their relationship with their children.“Good” Parents Tell Jokes: 63% of individuals with good parent relationships reported their parents used humor. Researcher's Opinion: “My hope is that people can learn to use humor as an effective parenting tool, not only to diffuse tension but develop resilience and cognitive and emotional flexibility in themselves and model it for their children,” said Benjamin Levi, professor of pediatrics and humanities at Penn State College of Medicine.Important Episode Timestamps(00:00 - 00:54) Introduction & Meet the Hosts(00:54 - 02:08) Big Question: What's Your Best April Fools' Memory?(02:08 - 05:32) Family Pranks & Classic April Fools' Jokes(05:32 - 07:17) The History of April Fools' Day(07:17 - 09:06) Famous April Fools' Hoaxes(09:06 - 12:33) Why Humor is Essential in Parenting(12:33 - 14:44) How Laughter Builds Stronger Relationships(14:44 - 18:07) Funniest Family Traditions & Inside Jokes(18:07 - 24:25) Practical Ways to Add More Laughter to Parenting(24:25 - 26:42) Pro Move of the Week: Pull a Fun Prank on Your KidsAPD Pro Move:Try some humor this week. Learn a new dad joke or pull off a prank. Try to bring some joy to your home through humor and see what happens. Resources:All Pro Dad Jokes VaultKnock Knock Jokes20 Great Riddles For KidsWe love feedback, but can't reply without your email address. Message us your thoughts and contact info!Connect with Us: Ted Lowe on LinkedIn Bobby Lewis on LinkedIn BJ Foster on LinkedIn Subscribe on Apple Podcasts EXTRAS: Follow us: Instagram | Facebook | X (Twitter)Join 200,000+ other dads by subscribing to the All Pro Dad Play of the Day. Get daily fatherhood ideas, insight, and inspiration straight to your inbox.This episode's blog can also be viewed here on AllProDad.com. Like the All Pro Dad gear and mugs? Get your own in the All Pro Dad store.Get great content for moms at iMOM.com

Amy Ward, Student Engagement Manager at Penn State College of Medicine joins the In Route to discuss Alex Ovechkin's pursuit of Wayne Gretzky, Saquon Barkley's impact in Philly, and more! Plus, D and Z break down the early signings of NFL Free Agency, debate where the Yankees go from here in light of the Gerrit Cole injury, and more.

In this captivating episode of Taking Healthcare by Storm, delve into the world of expert insights as Quality Insights Medical Director Dr. Jean Storm engages in a thought-provoking and informative discussion with Michael McShane, MD, EdM, Assistant Professor of Medicine at the Penn State College of Medicine.A Note from Neeli: Advancing rural health through the LION Mobile ClinicLearn more about the LION Mobile Clinic.Services provided by the LION Mobile Clinic.If you have any topics or guests you'd like to see on future episodes, reach out to us on our website. This material was prepared by Quality Insights, a Quality Innovation Network-Quality Improvement Organization under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services (HHS). Views expressed in this material do not necessarily reflect the official views or policy of CMS or HHS, and any reference to a specific product or entity herein does not constitute endorsement of that product or entity by CMS or HHS. Publication number 12SOW-QI-ARPA-012425-GK

DJ & PK talked about the Orange Bowl matchup between the Notre Dame Fighting Irish and the Penn State Nittany Lions as they battle in the College Football Playoff Semifinal.

Matt & Pete share the latest on the Fighting Irish heading into their semifinal matchup with Penn State on Thursday night. Tune in for injury updates on Jeremiyah Love and Abdul Carter, what Marcus Freeman shared with press this week as well as predictions for the matchup in South Florida. Can Riley Leonard take this game on his back like he did against Georgia? Will the defense get pressure on Drew Allar? Can Jadarian Price take over the workload if Love is not 100%. Future Fans: helping little kids become BIG fans, find out more at FutureFans.com  Learn more about your ad choices. Visit podcastchoices.com/adchoices

Oddstrader The first of two College Football Playoffs is set for South Florida with a couple of familiar foes, at least historically. These teams met...

In celebration of the Harvard Macy Institute's 30th anniversary, this blog & podcast series honors the remarkable individuals who have shaped and supported our community over the years. These accomplished educators, leaders, and champions of health professions education have contributed to the institute's enduring legacy. Through their leadership, innovation, and commitment to advancing education, they continue to inspire and guide future generations. Join us as we highlight their journeys, achievements, and reflections on the impact of HMI on their professional lives and the wider global community.  This episode of the Harvard Macy Institute podcast features Dr. Terry Wolpaw, a nationally recognized leader and innovator in medical education. She shares her journey from clinician to educationalist, highlighting the importance of shifting from a teacher-centered to a learner-centered approach.  Dr. Wolpaw discusses her experiences at Case Western Reserve and Penn State College of Medicine, where she led major curriculum changes. Key to her success, she says, was the ability to articulate a vision, assemble a strong team, and foster an environment of adaptive thinking.  She also reflects on the challenges of leading change and the importance of knowing when to step back and let go. This episode offers valuable insights for health professional educators at any stage of career who are navigating the complexities of medical education and curriculum design.  Terry Wolpaw has served as the vice dean for educational affairs at Penn State College of Medicine where she oversaw undergraduate, graduate, and continuing education. She has also served as the associate dean for curricular affairs at Case Western Reserve University School of Medicine. Among her many accomplishments was working to secure two five-year AMA grant awards at Penn State, both envisioning and promoting health system science as a core component of curricular design. She received one of the first American College of Rheumatology Clinician Scholar Educator career development awards, which catalyzed her interest in student-centered learning. Her educational scholarship has focused on the expression of students' clinical reasoning and uncertainties. She developed the SNAPPS technique for learners' case presentations to preceptors, which is used with medical students, residents and physician assistant students both nationally and internationally. Dr. Wolpaw is an alumna of the Program for Educators in Health Professions and Leading Innovation in Health Care and Education. Since then, she has served as faculty in the Program for Educators in Health Professions. In 2005, she played a key role in introducing sessions focused on posters and abstracts. This focus soon expanded into the broader theme of the Educator as a Scholar. This theme remains an integral part of the program today.

Audrey & Jon react to the selection of the Nittany Lions as the number six seed in the 2024 College Football Playoff. Penn State will host a first round playoff game against SMU in Beaver Stadium on Dec. 21st at noon ET. What is the path for James Franklin and his team? Can they make a deep run and how will they build off the Big Ten Championship offensive success? Will Drew Allar shine on the biggest stage and what adjustments will the defense need to make? Plus, will anyone ever call a hold on an offensive lineman against Abdul Carter?

Subscribe to Blue White Illustrated on YouTube: https://bit.ly/3KzEcqKCheck out the site too! - https://bit.ly/3u8dilDPenn State's potential bowl path is set! Check out athletictravel.com to book your reservation for the potential trip!On Sunday afternoon, the Penn State Nittany Lions football team discovered its destiny in the College Football Playoff. The committee rewarded the team's Big Ten schedule and its close losses to Ohio State and Oregon with the sixth seed in the playoff bracket. Penn State fell only one spot after losing in the Big Ten Championship game to fourth in the overall playoff rankings. With the conference champions getting byes into the first round, Penn State was the second non-conference champion in the playoff, behind Texas in the fifth spot. Join the Penn State Football Playoff Seeding Reaction Show as we discuss the team's first-round matchup against the 11th-seeded SM Mustangs, who beat out Alabama for the final spot in the playoff bracket. Blue White Illustrated experts Sean Fitz and Nate Bauer join the show live from Indianapolis to discuss how the playoff committee handled the playoff bracket, their thoughts about Penn State's matchup with SMU, and the team's overall chances of making a run at a national championship. Check out the show on our YouTube Channel, embedded on the site, or wherever you get your podcasts. Did Penn State get the best possible path?As Bauer pointed out during the run-up to conference championship weekend, the biggest debate around college football would be about penalizing participation in those games. Penn State was not penalized for losing to the top-ranked team. ESPN's Reece Davis asked Playoff Committee Chairman Ward Manuel about just how fair it was for Oregon and Penn State to get drastically different paths foward. "It turns out, the way things have fallen, it might be the six seed instead that is deemed more advantageous. Oregon, the only undefeated team in the country. You guys have deemed them the best team in this playoff. They are the Big Ten champions, and they just beat Penn State. And then when you look at their quarter-final game against either Ohio State or Tennessee, it might be that the ducks have a more disadvantageous road than the six-seed Penn State does in taking on an SMU team that barely made it in, and Boise State, who is not quite as highly ranked."Manuel deferred answering the question, saying that it was his committee's job to rank the top 25 teams in the country. From there, the rules of automatic byes in the playoffs changed the picture for teams in the field. But it stands to reason that Penn State's path is favorable. We discuss those notions on the show as well. What we know about SMU From there, we discuss what we know about the first-round matchup with SMU, which will be held at Beaver Stadium on Dec. 21st. We give you a quick preview of the players you need to know and how the team has played so far this season. #PennState  #NittanyLions  JOIN Blue White Illustrated: https://www.on3.com/teams/penn-state-nittany-lions/join/?plan=annualSUBSCRIBE to Blue White Illustrated on YouTube and enable alerts - new highlights and videos uploaded regularly: https://www.youtube.com/c/bluewhiteillustratedvideo?sub_confirmationGet the 2024 Penn State Football Preview Magazine at https://bit.ly/PSU24PreviewBookmark our homepage: https://www.on3.com/teams/penn-state-nittany-lions/Subscribe to BWI Magazine and Newsletters:  https://bluewhiteonline.com Download our podcasts: https://cms.megaphone.fm/channel/LRL3155877513?selected=DSVV2664982394Like us on Facebook https://www.facebook.com/BlueWhiteIllustrated/Follow us on Twitter https://twitter.com/PennStateOn3Sound effects obtained from https://www.zapsplat.com

If you're over the age of 65 and you are discharged from the hospital, there is a 1 in 5 chance that you will be back in the hospital in the next 30 days. Going to the hospital is an intense experience. Older adults are especially vulnerable to problems that arise from hospitalization. They see more health care providers, have more complicated chronic health conditions, take more medications, and are more likely to experience cognitive decline. Hospitals navigate many obstacles to make successful discharges and transition each patient's care to the next provider. It helps to understand those obstacles within the healthcare system, but also to know how you can be an effective advocate for yourself or your family member.Dr. Nicole Osevala, the Chief of Geriatric Medicine at the Penn State College of Medicine and the Hershey Medical Center, explains in this episode the elements of a safe care transition from the hospital.

Hour 1 with Joe Starkey: Starkey Six Pack. Tonight could be an incredible night at PPG Paints Arena as Evgeni Malkin is one goal away from 500 and Sidney Crosby one point shy of 1,600. Could Sidney Crosby eclipse Jaromir Jagr for second all-time in NHL history? Steelers QBs and George Pickens talk. We're dreaming of a Pitt-Penn State College Football Playoff game.

Eli Holstein is the catalyst behind Pitt's run and the offense leading the way. Pat Narduzzi's defense is typically a big strength, but Kade Bell's offense is taking Pitt to completely new heights. Jeff Patton join to tell us about Starkey's Card of the Week.

Pitt (22) is ranked for the first time this season and joins Penn State (4) in the Top 25 as we DREAM about a potential Pitt-Penn State College Football Playoff game.

Faculty development is always evolving, and new faculty development techniques like Master Adaptive Learning (MAL) equip educators to adapt their teaching to fresh, evidence-based methods. In this episode, Drew M. Keister, MD, shares the ongoing work of STFM's Faculty Development Collaborative to develop faculty development competencies, and facilitate discussions on faculty development, competency-based medical education, as well as how to create an environment conducive to master adaptive learning.Hosted by Saria Saccocio, MD, MHA, FAAFPCopyright © Society of Teachers of Family Medicine, 2024Resources:STFM Collaborative List - sign up for the Faculty Development Collaborative (note - you will need to sign into your STFM account)The Master Adaptive Learner - eBook by by Cutrer et alTraining Future Family Physicians to Become Master Adaptive Learners - Family Medicine Envisioning the Master Adaptive Learner - Resources from the AMASTFM Competency-Based Medical Education ToolkitWhy the Physician of the Future is a Master Adaptive Learner - AMA4 Personal Traits that Boost the Master Adaptive Learner Process - AMAGuest Bio:Drew Keister, MD, is a Lehigh Valley native who returned to join the LVHN Family Medicine Department in 2008. He attended Cornell University and attended Penn State College of Medicine in Hershey, the sweetest place on Earth. He completed his residency at the Andrews Air Force Base (AFB), where he was introduced to the fundamentals of Osteopathy. He joined the faculty at Offutt AFB's family medicine residency, in Nebraska. He attended the UNC Faculty Development Fellowship. Drew participated in the LVHN FM residency's P4 (Preparing the Personal Physician for Practice) national pilot experiment. He has served as the primary care clerkship director, the Associate Program Director and Program Director. In 2017, he became Vice Chair for Education. He remains an active faculty member in the residency and has broadened his focus to include CME, fellowship programs, medical student education, predoctoral training, and the new family medicine residency in Schuylkill County. In addition, he serves as the Vice CHair of the STFM Faculty Development Collaborative and presents nationally on faculty development topics, especially around Master Adaptive Learning, Individualized Education Plans, and Competency-Based Medical Education. Link:https://www.stfm.org/stfmpodcast092024 

It's been ten years since the spotted lanternflies began showing up in Pennsylvania. Brian Walsh, Spotted Lanternfly Researcher at Penn State College of Agricultural Sciences began noticing the insects when he was a landscaper years ago. "I was running a landscaping business, and it lanternfly landed very close to where we worked from just a few miles. And we realized that what we were seeing on the ground didn't really match up with what we were being told by some of the government agencies that were responding. And so we had to do our own research to figure out what would work to kill them and do our best with, helping our customers to, help keep their trees alive. At the time, we thought that all the trees and shrubs that they were feeding on were going to be killed by lanternfly, "said Walsh. Soon after, Walsh joined the researches at Penn State College. He learned spotted lanternflies are prolific, and they feed on just about anything. "It has a hugely varied diet and it uses the entire landscape. A lot of, insect pests will focus on one or maybe a few, different host plants, in, throughout the landscape. But spotted lanternfly is able to use pretty much anything that's available to it from all the way down to weeds and weedy grasses right up through full sized trees, depending on where they are in the lifecycle stage. And because it can move freely through a huge amount of our landscape, it's like trying to catch a moving target when you're trying to control, "said Walsh. For years, it was believed that the spotted lanternflies only fed on grapes, and trees of haven. However, researches have found the invasive species will feed on black walnuts, maple trees, and more. "We know that there are several others that are also preferred hosts. And it kind of depends on the time of the year when the nymphs are very small, they'll feed on just about anything shrubs, small shrubs, weedy plants, just perennial weeds and roadside ditches. They're happy that anything that's off that they can get a meal from, they'll do it and they move. They move constantly. When we see the fourth in stars, and early adults, it's really where we see the, the lanternfly start to congregate more and we'll start seeing them grouped up more. We see black walnut is a very common host at that time period. Black walnut is very common and very important hardwood tree in Pennsylvania. And there's a lot of it, especially through the southern part of the state. They really prefer the black walnut. And then later on in the fall, we see a lot of movement towards maple trees, red maple syrup, silver maples. And they will they will use this to finish out the lifecycle and lay their eggs. So it's a it's a moving target. It's a moving diet, "said Walsh. Even though ten years have passed, it is still important that the spotted lanternflies are killed because they cause so much damage to our crops. "If you're not comfortable using insecticides, you can. You can just squash them with a fly swatter. Stomp on them. The important thing is, if you find them in a place where they're not known to be yet, make sure to report them. Report them to the Department of Agriculture, "said Walsh.    Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.

For Information Like Degrees Offered, Annual Costs, Etc., Please Click The Banner Below: The Agricultural College Episode is designed to profile agricultural trade schools, junior colleges, colleges and universities around the U.S.  This episode is an effort to replicate the conversation that prospective students, parents and ag teachers might have with agricultural schools at trade show like the National FFA Convention. Penn State is a very storied and very well known university, but did you know it all started with agriculture?  On today's Ag College Episode we get to delve into that history and see what it has become throughout the entire commonwealth campus system.  Hundreds of opportunities await agriculture students in State College, Pennsylvania and we have four great guests to tell you about all them!

Dr. Adrienne Boissy, MD, MA, is a pioneering executive in healthcare innovation, currently serving as the Chief Medical Officer of Qualtrics, an experience management company. She is also a staff neurologist at the Cleveland Clinic and is the former Chief Experience Officer there. During her tenure, she led transformative global initiatives to enhance the experience of humans who touch healthcare, introducing evidence-based communication skills training that redefined patient experience standards, novel metrics, best practice implementation, and research. Dr. Boissy's impact extends to fostering global dialogue as the prior co-chair of the Empathy and Innovation summit, the largest independent summit on patient experience in the world, and as Editor Emeritus of the Journal of Patient Experience. She is also a frequently sought speaker and accomplished author, known for her insightful publications on patient experience innovation, consumerism, telehealth, empathy, and burnout. With a strong academic foundation, earning her Doctor of Medicine from Penn State College of Medicine, a bachelor's degree from Boston University, and a Master's in Bioethics from Case Western Reserve University, Dr. Boissy embodies a holistic approach to healthcare. She has received prestigious grants from the National Multiple Sclerosis Society and the Arnold P. Gold Foundation, furthering her dedication to ethical and humanistic healthcare. Dr. Boissy's influence as a speaker and thought leader is evident in her TED talks and publications featured in renowned outlets, like The Wall Street Journal and Forbes, showcasing her relentless pursuit of improving the patient and provider experience on a global scale. Join us as we explore Dr. Adrienne Boissy's multifaceted contributions to neurology, bioethics, and experience in healthcare. Welcome, Dr. Boissy!

Thwaites Glacier located in Antarctica, is an unusually broad and vast glacier. Known as The 'Doomsday Glacier', scientist say it is rapidly melting. Sridhar Anandakrishnan is a glaciologist and professor at Penn State College of Earth and Mineral Sciences. He explains the danger of global warming's effect on Thwaites Glacier, with the increased melting from the glacier causing sea level rise across the globe. Reporter | Camera:  Aaron Fedor, Producer: Kathleen McLaughlin, Editor: Kyle Dubiel 

Gavin Macgregor-Skinner is a Senior Director at ISSA – The Worldwide Cleaning Trade Association. He has more than 30 years of technical experience in responding to infectious disease outbreaks and emergency management. He is also an Associate Professor in the Department of Public Health Sciences at Penn State College of Medicine and teaches three 15-week graduate courses on Public Health. Macgregor-Skinner has appeared on CNN, Fox News, BBC and many other news outlets to share his expertise on High Consequence Pathogens.   Steven Cooper is an engineer with a technical specialty in the research and development of water-based electrostatic spray systems. He has developed innovative core technology and commercial products related to air-atomizing induction-charging (AAIC) spray systems. Mr. Cooper is an engineer, a scientist, as well as an entrepreneur. He is the co-founder of ByoPlanet/Good Salt LLC, and has been involved in establishing several other successful companies. Mr. Cooper received his undergrad and masters degrees from the University of Georgia and has been continuously involved with the UGA Applied Electrostatics Laboratory for over three decades.

  In the U.S., 16,000 children are diagnosed with cancer each year, and more children die from cancer than any other disease. Fighting, researching or finding a cure for childhood cancer is obviously as grave a topic as one could contemplate. But perhaps the annual dance marathon known simply as Thon, at the Bryce Jordan Center on the campus of Penn State University this weekend is one of the most joyful events staged anywhere or any time to raise money for such an illness that can bring so much sadness. Thon is a 46-hour, non-stop dance marathon that is the world's largest student-run philanthropy. Since its inception in 1973, Thon has raised more than $219 million to provide emotional and financial support to children and families that have been impacted by childhood cancer. The money generated by Thon goes to Four Diamonds at Penn State Children's Hospital in Hershey. On The Spark Monday, Suzanna Graney, Executive Director of Four Diamonds at Penn State Health Children's Hospital, said Four Diamonds has benefited from Thon since 1977,"e have been collaborative partners ever since, making it possible for Four Diamonds to cover the cost of care for all of our Four Diamonds families at, our Children's Hospital in Hershey. And to be a Four Diamonds family, your child would be diagnosed under the age of 22, living in Pennsylvania and getting your primary oncology care from Penn State Health Children's Hospital. We are covering all those costs that are not covered by insurance or other means, taking that financial pressure off of the family, because when cancer happens to a child, it happens to the entire family. So the other thing that we're able to do is provide a lot of support services for the patient and the family members to have everything that they need mentally, socially, emotionally, spiritually as they're walking this path together. So all of those specialty services like child life and music therapy and art therapy are covered for all of those kids in those families." Much of the money raised by Thon goes toward research. Graney added,"Finding new ways to use the current drugs that we have. Finding new applications of new drugs or new therapies using the body's immune system differently to activate your immune system to fight cancer is one of the biggest things that has happened in the last ten years. It's been exciting to be on the precipice of new discovery, and to be able to find what we talk about as local research that has a global impact. The research that's happening in Hershey, Pennsylvania, has the potential to change the world for kids everywhere. We're really excited because of Thon's steady support and the community support we've been funding, a number of researchers at the Penn State College of Medicine, two of those labs have been funded for more than a decade through Thon and Four Diamond support, and they are both on the cusp of opening clinical trials for kids, in the coming year, which means that what we've learned in that lab is now ready to go into patient care." Will Vincent, the Executive Director of Thon was asked what makes it special,"It is an entirely student run organization. But on the other side, we also have a tremendous amount of outpouring of support from Penn State alumni, corporate sponsors, and just the overall Penn State community and beyond. So there are students on this campus that work tirelessly all year long. Thon has become so much more than just a weekend in February. So our student volunteers work all year long. But the support that we get from every single person that has heard of Thon's mission and wanted to push it forward is absolutely tremendous. So it is a huge community that expanded. Its so far out just beyond Penn State's campus and just State College." Last year, Thon raised more $15 million.Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.

Dan Shapiro is a man on a mission to help physicians, other providers and the medical healthcare administrators understand the reality of healthcare provider burnout. He is currently the Director of the Chartis Center for Burnout Solutions, where he and his team assist leaders of multi-hospital systems with efforts to reduce burnout and the turnover of high-value physicians, nurses, advanced practice providers, and other staff. Dan's education goes back to my alma mater, Vassar College. He graduated with a BA in Psychology before going to the University of Florida for his doctorate in clinical psychology. He completed a post doctoral degree in Medical Crisis Interventions at Harvard University. He held faculty positions at the University of Arizona as well as at Penn State rising to the Chair and Professor of Humanities at Penn State College of Medicine. In 2017, he developed a systematic method for assessing and addressing burnout leading to consulting services focused on multi-hospital systems. In 2023, he left his role as Vice Dean and Chair to pursue the reduction of burnout full time with colleagues at Chartis. Dan is a frequent contributor to thought leadership in the physician burnout space. In 2003, Random House published his landmark memoir about one physician's burnout, titled, “Delivering Doctor Amelia,” which was required reading at some colleges and medical schools. He's written two other books, also for Random House. Dan's additional writings have appeared or been featured in, among others, the New York Times, Proceedings of the National Academies of Science, the New England Journal of Medicine, JAMA, Academic Medicine, and NPR's All Things Considered. As a hobby, he worked for ten years as a weekly consultant to the hit television shows Grey's Anatomy, Private Practice, How to Get Away with Murder and on-camera for the Discovery, National Geographic, and FYI channels. Please enjoy my conversation with Dan Shapiro, Dr. M

Kate met Aisha when she moved into her student home at Milton Hershey School in Hershey, Pennsylvania. Aisha lived across the hall. After graduating from MHS, Aisha earned a bachelor's degree in human biology from Brown University, where she participated in track and field and was a member of the Heptagonal Championship Team, the Ivy League women's track champions. She went on to complete a medical degree at the Penn State College of Medicine, where she won the Lehigh Valley Hospital Community Service Award, awarded to a medical student who displayed exemplary service in the community; and the Dean's Award, an academic scholarship awarded to a college student who displayed academic excellence. Aisha has been an emergency medicine physician at Greenwich Hospital in Greenwich, Connecticut since 2017. Reality Life with Kate CaseyTickets to Live Show 2/28: https://improv.com/irvine/event/reality+life+with+kate+casey/12128905/Patreon: http://www.patreon.com/katecaseyTwitter: https://twitter.com/katecaseyInstagram: http://www.instagram.com/katecaseycaTik Tok: http://www.tiktok.com/itskatecaseyCameo: https://cameo.com/katecaseyFacebook Group: https://www.facebook.com/groups/113157919338245Amazon.com: www.amazon.com/shop/katecaseySee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YUZ865. CME/MOC credit will be available until December 31, 2024.Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential ManagementPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partners, PVI, PeerView Institute for Medical Education, and CLL Society.SupportThis activity is supported by independent educational grants from AbbVie; AstraZeneca; Lilly; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.DisclosuresProf. John G. Gribben, MD, DSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen and Gilead Sciences/Kite.Grant/Research Support from AstraZeneca.John N. Allan, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca; BeiGene, Inc.; Epizyme, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; LAVA Therapeutics; Lilly; Pharmacyclics LLC; and TG Therapeutics, Inc.Grant/Research Support from BeiGene, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Speaker for AbbVie; BeiGene, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Allogene Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Lilly/Loxo Oncology, Inc.; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.Meghan C. Thompson, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research funding goes to Institution.Honoraria from Brazilian Association of Hematology; Curio Science; Dava Oncology; Hemotherapy and Cellular Therapy (ABHH); Intellisphere LLC; Massachusetts Medical Society; MJH Life Sciences; Phillips Group Oncology Communications; and VJHemOnc.Larry Marion has no financial interests/relationships or affiliations in relation to this activity.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YUZ865. CME/MOC credit will be available until December 31, 2024.Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential ManagementPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partners, PVI, PeerView Institute for Medical Education, and CLL Society.SupportThis activity is supported by independent educational grants from AbbVie; AstraZeneca; Lilly; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.DisclosuresProf. John G. Gribben, MD, DSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen and Gilead Sciences/Kite.Grant/Research Support from AstraZeneca.John N. Allan, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca; BeiGene, Inc.; Epizyme, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; LAVA Therapeutics; Lilly; Pharmacyclics LLC; and TG Therapeutics, Inc.Grant/Research Support from BeiGene, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Speaker for AbbVie; BeiGene, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Allogene Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Lilly/Loxo Oncology, Inc.; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.Meghan C. Thompson, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research funding goes to Institution.Honoraria from Brazilian Association of Hematology; Curio Science; Dava Oncology; Hemotherapy and Cellular Therapy (ABHH); Intellisphere LLC; Massachusetts Medical Society; MJH Life Sciences; Phillips Group Oncology Communications; and VJHemOnc.Larry Marion has no financial interests/relationships or affiliations in relation to this activity.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YUZ865. CME/MOC credit will be available until December 31, 2024.Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential ManagementPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partners, PVI, PeerView Institute for Medical Education, and CLL Society.SupportThis activity is supported by independent educational grants from AbbVie; AstraZeneca; Lilly; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.DisclosuresProf. John G. Gribben, MD, DSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen and Gilead Sciences/Kite.Grant/Research Support from AstraZeneca.John N. Allan, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca; BeiGene, Inc.; Epizyme, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; LAVA Therapeutics; Lilly; Pharmacyclics LLC; and TG Therapeutics, Inc.Grant/Research Support from BeiGene, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Speaker for AbbVie; BeiGene, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Allogene Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Lilly/Loxo Oncology, Inc.; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.Meghan C. Thompson, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research funding goes to Institution.Honoraria from Brazilian Association of Hematology; Curio Science; Dava Oncology; Hemotherapy and Cellular Therapy (ABHH); Intellisphere LLC; Massachusetts Medical Society; MJH Life Sciences; Phillips Group Oncology Communications; and VJHemOnc.Larry Marion has no financial interests/relationships or affiliations in relation to this activity.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YUZ865. CME/MOC credit will be available until December 31, 2024.Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential ManagementPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partners, PVI, PeerView Institute for Medical Education, and CLL Society.SupportThis activity is supported by independent educational grants from AbbVie; AstraZeneca; Lilly; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.DisclosuresProf. John G. Gribben, MD, DSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen and Gilead Sciences/Kite.Grant/Research Support from AstraZeneca.John N. Allan, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca; BeiGene, Inc.; Epizyme, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; LAVA Therapeutics; Lilly; Pharmacyclics LLC; and TG Therapeutics, Inc.Grant/Research Support from BeiGene, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Speaker for AbbVie; BeiGene, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Allogene Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Lilly/Loxo Oncology, Inc.; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.Meghan C. Thompson, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research funding goes to Institution.Honoraria from Brazilian Association of Hematology; Curio Science; Dava Oncology; Hemotherapy and Cellular Therapy (ABHH); Intellisphere LLC; Massachusetts Medical Society; MJH Life Sciences; Phillips Group Oncology Communications; and VJHemOnc.Larry Marion has no financial interests/relationships or affiliations in relation to this activity.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YUZ865. CME/MOC credit will be available until December 31, 2024.Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential ManagementPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partners, PVI, PeerView Institute for Medical Education, and CLL Society.SupportThis activity is supported by independent educational grants from AbbVie; AstraZeneca; Lilly; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.DisclosuresProf. John G. Gribben, MD, DSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen and Gilead Sciences/Kite.Grant/Research Support from AstraZeneca.John N. Allan, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca; BeiGene, Inc.; Epizyme, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; LAVA Therapeutics; Lilly; Pharmacyclics LLC; and TG Therapeutics, Inc.Grant/Research Support from BeiGene, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Speaker for AbbVie; BeiGene, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Allogene Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Lilly/Loxo Oncology, Inc.; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.Meghan C. Thompson, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research funding goes to Institution.Honoraria from Brazilian Association of Hematology; Curio Science; Dava Oncology; Hemotherapy and Cellular Therapy (ABHH); Intellisphere LLC; Massachusetts Medical Society; MJH Life Sciences; Phillips Group Oncology Communications; and VJHemOnc.Larry Marion has no financial interests/relationships or affiliations in relation to this activity.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YXF865. CME/MOC credit will be available until December 31, 2024.The ‘Clot' Thickens in the Hemophilia Story: Clinical Perspectives on Enhancing Outcomes With Innovative Non-Factor TherapyPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novo Nordisk, Inc.DisclosuresAmy Shapiro, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; and Sanofi-Genzyme.Grant/Research Support from Agios Pharmaceuticals, Inc.; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; Sanofi-Genzyme; and Takeda Pharmaceutical Company Limited.Speakers Bureau participant with CSL Behring; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Sanofi-Genzyme; and Takeda Pharmaceutical Company Limited.Other Financial or Material Support in the form as a board member of the Novo Nordisk Haemophilia Foundation. She is the Medical Director of the National Hemophilia Program and Coordinating Center of the American Thrombosis Hemostatis Network.Prof Pratima Chowdary, MD, FRCPATH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bayer Corporation; BioMarin/Boehringer Ingelheim Pharmaceuticals, Inc.; Centessa Pharmaceuticals plc/Johnson & Johnson Services, Inc.; CSL; Freeline; Novo Nordisk A/S; Pfizer; Sanofi; Swedish Orphan Biovitrum AB; and Takeda Pharmaceutical Company Limited/Chugai Pharmaceutical Co., Ltd.Grant/Research Support from Freeline; Novo Nordisk A/S; Pfizer; and Swedish Orphan Biovitrum AB.Speakers Bureau participant with BioMarin/Boehringer Ingelheim Pharmaceuticals, Inc.; Novo Nordisk A/S; Pfizer; Sanofi; Swedish Orphan Biovitrum AB; and Takeda Pharmaceutical Company Limited/Chugai Pharmaceutical Co., Ltd.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/MQE865. CME credit will be available until December 31, 2024.Achieving Next-Level Care in AML: Conversations on Targeted Platforms, Emerging Immunotherapies, and Implications for Precision MedicinePenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partners, PVI, PeerView Institute for Medical Education, and the HealthTree Foundation for Acute Myeloid Leukemia.SupportThis activity is supported by independent educational grants from AbbVie, Actinium Pharmaceuticals, Astellas, Kura Oncology, Inc., and Syndax.DisclosuresSergio A. Giralt, MD, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Actinium Pharmaceuticals, Inc.; Amgen Inc.; Celgene Corporation; Jazz Pharmaceuticals, Inc.; Johnson & Johnson, Inc.; Kite Pharma; Novartis Pharmaceuticals Corporation; Sanofi; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Actinium Pharmaceuticals, Inc.; Amgen Inc.; Celgene Corporation; Johnson & Johnson, Inc.; Miltenyi Biotec; Sanofi; and Takeda Pharmaceutical Company Limited.Selina Luger, MD, FRCPC, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Amgen Inc.; Bristol Myers Squibb; and Marker Therapeutics, Inc.Grant/Research Support from Onconova Therapeutics, Inc.Speaker for Amgen Inc.Pinkal Desai, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Bristol Myers Squibb; Kura Oncology, Inc.; Rigel Pharmaceuticals, Inc.; and Servier Laboratories.Ghayas Issa, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Kura Oncology, Inc. and Novartis Pharmaceuticals Corporation.Grant/Research Support from Cullinan Oncology, Inc; Kura Oncology, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Syndax.Tapan Kadia, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Daiichi Sankyo Inc.; Genentech, Inc.; Genzyme Corporation; Jazz Pharmaceuticals, Inc.; Liberum Capital Limited; Novartis Pharmaceuticals Corporation; Pfizer; PinotBio, Inc.; Pulmotect, Inc.; Sanofi; Servier Laboratories.Grant/Research Support from AbbVie; Amgen Inc.; Ascentage Pharma Group; Astellas Pharma US, Inc.; Astex Pharmaceuticals; AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Cellenkos Inc.; Cyclacel Pharmaceuticals, Inc.; Delta-Fly Pharma, Inc.; Genentech, Inc.; GenFleet Therapeutics; GlycoMimetics; Iterion Therapeutics; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Pfizer; Pulmotect, Inc.; Regeneron Pharmaceuticals Inc.; and SELLAS Life Sciences Group. Grant/Research Support Paid to Institution.Speakers Bureau participant with Biologix USA, Inc.; CURE Pharmaceutical; and Hikma Pharmaceuticals.Honorarium from Genzyme Corporation.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YXF865. CME/MOC credit will be available until December 31, 2024.The ‘Clot' Thickens in the Hemophilia Story: Clinical Perspectives on Enhancing Outcomes With Innovative Non-Factor TherapyPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novo Nordisk, Inc.DisclosuresAmy Shapiro, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; and Sanofi-Genzyme.Grant/Research Support from Agios Pharmaceuticals, Inc.; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; Sanofi-Genzyme; and Takeda Pharmaceutical Company Limited.Speakers Bureau participant with CSL Behring; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Sanofi-Genzyme; and Takeda Pharmaceutical Company Limited.Other Financial or Material Support in the form as a board member of the Novo Nordisk Haemophilia Foundation. She is the Medical Director of the National Hemophilia Program and Coordinating Center of the American Thrombosis Hemostatis Network.Prof Pratima Chowdary, MD, FRCPATH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bayer Corporation; BioMarin/Boehringer Ingelheim Pharmaceuticals, Inc.; Centessa Pharmaceuticals plc/Johnson & Johnson Services, Inc.; CSL; Freeline; Novo Nordisk A/S; Pfizer; Sanofi; Swedish Orphan Biovitrum AB; and Takeda Pharmaceutical Company Limited/Chugai Pharmaceutical Co., Ltd.Grant/Research Support from Freeline; Novo Nordisk A/S; Pfizer; and Swedish Orphan Biovitrum AB.Speakers Bureau participant with BioMarin/Boehringer Ingelheim Pharmaceuticals, Inc.; Novo Nordisk A/S; Pfizer; Sanofi; Swedish Orphan Biovitrum AB; and Takeda Pharmaceutical Company Limited/Chugai Pharmaceutical Co., Ltd.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/BWR865. CME/MOC credit will be available until December 31, 2024.Exploring Unmarked Territory in MDS: Taking Command and Enhancing Care With Team-Based Diagnosis and TreatmentPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported through educational grants from Astex Pharmaceuticals, Inc., Bristol Myers Squibb, Geron, Karyopharm Therapeutics, and Novartis Pharmaceuticals Corporation.DisclosuresMaría Díez Campelo, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Agios Pharmaceuticals Inc.; Blueprint Medicines; Bristol Myers Squibb; GlaxoSmithKline; Hemavant Sciences; Novartis; and Syros Pharmaceuticals, Inc.Rory M. Shallis, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb; Curio Bioscience; Gilead Sciences, Inc.; Rigel Pharmaceuticals, Inc.; and Servier Pharmaceuticals.Aditi Shastri, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kymera Therapeutics; and Rigel Pharmaceuticals, Inc.Grant/Research Support from Kymera Therapeutics.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/BWR865. CME/MOC credit will be available until December 31, 2024.Exploring Unmarked Territory in MDS: Taking Command and Enhancing Care With Team-Based Diagnosis and TreatmentPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported through educational grants from Astex Pharmaceuticals, Inc., Bristol Myers Squibb, Geron, Karyopharm Therapeutics, and Novartis Pharmaceuticals Corporation.DisclosuresMaría Díez Campelo, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Agios Pharmaceuticals Inc.; Blueprint Medicines; Bristol Myers Squibb; GlaxoSmithKline; Hemavant Sciences; Novartis; and Syros Pharmaceuticals, Inc.Rory M. Shallis, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb; Curio Bioscience; Gilead Sciences, Inc.; Rigel Pharmaceuticals, Inc.; and Servier Pharmaceuticals.Aditi Shastri, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kymera Therapeutics; and Rigel Pharmaceuticals, Inc.Grant/Research Support from Kymera Therapeutics.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/MQE865. CME credit will be available until December 31, 2024.Achieving Next-Level Care in AML: Conversations on Targeted Platforms, Emerging Immunotherapies, and Implications for Precision MedicinePenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partners, PVI, PeerView Institute for Medical Education, and the HealthTree Foundation for Acute Myeloid Leukemia.SupportThis activity is supported by independent educational grants from AbbVie, Actinium Pharmaceuticals, Astellas, Kura Oncology, Inc., and Syndax.DisclosuresSergio A. Giralt, MD, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Actinium Pharmaceuticals, Inc.; Amgen Inc.; Celgene Corporation; Jazz Pharmaceuticals, Inc.; Johnson & Johnson, Inc.; Kite Pharma; Novartis Pharmaceuticals Corporation; Sanofi; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Actinium Pharmaceuticals, Inc.; Amgen Inc.; Celgene Corporation; Johnson & Johnson, Inc.; Miltenyi Biotec; Sanofi; and Takeda Pharmaceutical Company Limited.Selina Luger, MD, FRCPC, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Amgen Inc.; Bristol Myers Squibb; and Marker Therapeutics, Inc.Grant/Research Support from Onconova Therapeutics, Inc.Speaker for Amgen Inc.Pinkal Desai, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Bristol Myers Squibb; Kura Oncology, Inc.; Rigel Pharmaceuticals, Inc.; and Servier Laboratories.Ghayas Issa, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Kura Oncology, Inc. and Novartis Pharmaceuticals Corporation.Grant/Research Support from Cullinan Oncology, Inc; Kura Oncology, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Syndax.Tapan Kadia, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Daiichi Sankyo Inc.; Genentech, Inc.; Genzyme Corporation; Jazz Pharmaceuticals, Inc.; Liberum Capital Limited; Novartis Pharmaceuticals Corporation; Pfizer; PinotBio, Inc.; Pulmotect, Inc.; Sanofi; Servier Laboratories.Grant/Research Support from AbbVie; Amgen Inc.; Ascentage Pharma Group; Astellas Pharma US, Inc.; Astex Pharmaceuticals; AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Cellenkos Inc.; Cyclacel Pharmaceuticals, Inc.; Delta-Fly Pharma, Inc.; Genentech, Inc.; GenFleet Therapeutics; GlycoMimetics; Iterion Therapeutics; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Pfizer; Pulmotect, Inc.; Regeneron Pharmaceuticals Inc.; and SELLAS Life Sciences Group. Grant/Research Support Paid to Institution.Speakers Bureau participant with Biologix USA, Inc.; CURE Pharmaceutical; and Hikma Pharmaceuticals.Honorarium from Genzyme Corporation.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/BWR865. CME/MOC credit will be available until December 31, 2024.Exploring Unmarked Territory in MDS: Taking Command and Enhancing Care With Team-Based Diagnosis and TreatmentPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported through educational grants from Astex Pharmaceuticals, Inc., Bristol Myers Squibb, Geron, Karyopharm Therapeutics, and Novartis Pharmaceuticals Corporation.DisclosuresMaría Díez Campelo, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Agios Pharmaceuticals Inc.; Blueprint Medicines; Bristol Myers Squibb; GlaxoSmithKline; Hemavant Sciences; Novartis; and Syros Pharmaceuticals, Inc.Rory M. Shallis, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb; Curio Bioscience; Gilead Sciences, Inc.; Rigel Pharmaceuticals, Inc.; and Servier Pharmaceuticals.Aditi Shastri, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kymera Therapeutics; and Rigel Pharmaceuticals, Inc.Grant/Research Support from Kymera Therapeutics.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/JXH865. CME credit will be available until December 31, 2024.Toward a Brighter Future for Preventing COVID-19 in Patients With Hematologic Malignancies: Leveraging the Power of Current Strategies and Next-Generation AgentsPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an independent educational grant from AstraZeneca LP.DisclosuresShmuel Shoham, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Adagio Therapeutics, Inc.; Adamis Pharmaceuticals Corporation; Immunome; Karius, Inc.; Pfizer; and SCYNEXIS, Inc.Grant/Research Support from Ansun Biopharma; Cidara Therapeutics, Inc.; F2G; Octapharma USA, Inc.; and Zeteo Biomedical LLC.Ghady Haidar, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca and Karius, Inc.Grant/Research Support from Allovir; AstraZeneca; Karius, Inc.; and National Institutes of Health (NIH).Speaker for International AIDS Society and MDOutlook.Carol Ann Huff, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Janssen Pharmaceuticals, Inc. and Sanofi.Haleh Simi has no financial interests/relationships or affiliations in relation to this activity.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/JXH865. CME credit will be available until December 31, 2024.Toward a Brighter Future for Preventing COVID-19 in Patients With Hematologic Malignancies: Leveraging the Power of Current Strategies and Next-Generation AgentsPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an independent educational grant from AstraZeneca LP.DisclosuresShmuel Shoham, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Adagio Therapeutics, Inc.; Adamis Pharmaceuticals Corporation; Immunome; Karius, Inc.; Pfizer; and SCYNEXIS, Inc.Grant/Research Support from Ansun Biopharma; Cidara Therapeutics, Inc.; F2G; Octapharma USA, Inc.; and Zeteo Biomedical LLC.Ghady Haidar, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca and Karius, Inc.Grant/Research Support from Allovir; AstraZeneca; Karius, Inc.; and National Institutes of Health (NIH).Speaker for International AIDS Society and MDOutlook.Carol Ann Huff, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Janssen Pharmaceuticals, Inc. and Sanofi.Haleh Simi has no financial interests/relationships or affiliations in relation to this activity.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/JXH865. CME credit will be available until December 31, 2024.Toward a Brighter Future for Preventing COVID-19 in Patients With Hematologic Malignancies: Leveraging the Power of Current Strategies and Next-Generation AgentsPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an independent educational grant from AstraZeneca LP.DisclosuresShmuel Shoham, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Adagio Therapeutics, Inc.; Adamis Pharmaceuticals Corporation; Immunome; Karius, Inc.; Pfizer; and SCYNEXIS, Inc.Grant/Research Support from Ansun Biopharma; Cidara Therapeutics, Inc.; F2G; Octapharma USA, Inc.; and Zeteo Biomedical LLC.Ghady Haidar, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca and Karius, Inc.Grant/Research Support from Allovir; AstraZeneca; Karius, Inc.; and National Institutes of Health (NIH).Speaker for International AIDS Society and MDOutlook.Carol Ann Huff, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Janssen Pharmaceuticals, Inc. and Sanofi.Haleh Simi has no financial interests/relationships or affiliations in relation to this activity.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/JXH865. CME credit will be available until December 31, 2024.Toward a Brighter Future for Preventing COVID-19 in Patients With Hematologic Malignancies: Leveraging the Power of Current Strategies and Next-Generation AgentsPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an independent educational grant from AstraZeneca LP.DisclosuresShmuel Shoham, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Adagio Therapeutics, Inc.; Adamis Pharmaceuticals Corporation; Immunome; Karius, Inc.; Pfizer; and SCYNEXIS, Inc.Grant/Research Support from Ansun Biopharma; Cidara Therapeutics, Inc.; F2G; Octapharma USA, Inc.; and Zeteo Biomedical LLC.Ghady Haidar, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca and Karius, Inc.Grant/Research Support from Allovir; AstraZeneca; Karius, Inc.; and National Institutes of Health (NIH).Speaker for International AIDS Society and MDOutlook.Carol Ann Huff, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Janssen Pharmaceuticals, Inc. and Sanofi.Haleh Simi has no financial interests/relationships or affiliations in relation to this activity.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/JXH865. CME credit will be available until December 31, 2024.Toward a Brighter Future for Preventing COVID-19 in Patients With Hematologic Malignancies: Leveraging the Power of Current Strategies and Next-Generation AgentsPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an independent educational grant from AstraZeneca LP.DisclosuresShmuel Shoham, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Adagio Therapeutics, Inc.; Adamis Pharmaceuticals Corporation; Immunome; Karius, Inc.; Pfizer; and SCYNEXIS, Inc.Grant/Research Support from Ansun Biopharma; Cidara Therapeutics, Inc.; F2G; Octapharma USA, Inc.; and Zeteo Biomedical LLC.Ghady Haidar, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca and Karius, Inc.Grant/Research Support from Allovir; AstraZeneca; Karius, Inc.; and National Institutes of Health (NIH).Speaker for International AIDS Society and MDOutlook.Carol Ann Huff, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Janssen Pharmaceuticals, Inc. and Sanofi.Haleh Simi has no financial interests/relationships or affiliations in relation to this activity.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

Dr. Erdem Tabdanov is Assistant Professor in the Department of Pharmacology at Penn State College of Medicine and also a Member of the Penn State Cancer Institute. He studies the mechanical and structural aspects of cells to better understand how cells physically move, sense their environments, and accomplish their various functions. This is very relevant to cancer biology and understanding the immune system. Some of Erdem's hobbies outside of science include working out at the gym, calligraphy, sketching, digital art, and other visual arts. He is also considering adopting a cat. His interest in digital art emerged from his desire to put the story of his research together in compelling figures and schematics for journal articles. He received his bachelor's degree in biotechnology and his MSc in chemistry and molecular and cellular biotechnology from Lomonosov Moscow State Academy of Fine Chemical Technology (MITHT). He was awarded his PhD in cancer research from L'Institut Curie in Paris. Afterwards, Erdem conducted postdoctoral research at the University of Pennsylvania and Columbia University. He then served in the 82nd Airborne Division of the U.S. army for four years. Erdem completed a postdoctoral fellowship at the University of Minnesota before joining the faculty at Penn State where he is today. In this interview, Erdem shares more about his life and science.

Gillian is from the larger Philadelphia area and initially studied Philosophy and Psychology at the University of Scranton and worked in social services as a Case Manager after college. She then transitioned to Vaccine Development NIH-funded research as a clinical coordinator at the University of Vermont while taking pre-med classes. She attended medical school at Penn State College of Medicine, where she also earned her Masters in Education and was recognized with the Leonard Tow Humanism in Medicine award and the Gold Humanism Honor Society. During medical school, she also held multiple statewide and national positions such as Chair for the Committee on Bioethics & Humanities for the American Medical Association-Medical Student Section, Board of Trustee for the Pennsylvania Medical Society, State Director on the Pennsylvania Political Action Committee Board of Directors for the Pennsylvania Medical Society. She was served as an Editorial Fellow with the AMA Journal of Ethics in 2019. She matched at TJUH in Internal Medicine where she was recognized with multiple teaching awards including Hobart Amory Hare Resident Teaching Award, Alpha Omega Alpha Honor Society and teaching award, and the Darilyn Moyer, MD, FACP Professionalism Award for Trainees in Southeastern PA. She is interested in a career in academic hospital medicine and medical education crafting curriculum that incorporates health system science and humanism topics in medicine.___0:00 - Intro1:29 - Statistics About Internal Medicine3:55 - What Is Internal Medicine?7:25 - Why Internal Medicine?15:18 - What Was IM Residency Like?17:23 - Plans for Designing a Curriculum19:22 - Shooting Incident at the Hospital23:02 - Best Thing About Being an IM Doctor26:09 - Worst Thing About Being an IM Doctor27:14 - Work Intensity and an Average Day as a Resident34:14 - The Best Year of Residency35:19 - An Average Outpatient Day/Week38:32 - If I Give You $100 Million, What Would You Do?43:56 - Things You Wish You Knew Before Coming Into IM45:33 - Characteristics of a Student Best for IM50:00 - Advice for People Looking Into Internal Medicine51:22 - Maximizing Competitiveness Going Into IM Residency54:03 - Things Learned From Residency56:53 - Common Mistakes1:00:49 - Positive Qualities & Characteristics You Admire1:03:05 - Closing Message1:04:14 - Outro__Resources___View the Show Notes Page for This Episode for a transcript and more information: zhighley.com/podcast___Connect With ZachMain YouTube: @ZachHighley Newsletter: https://zhighley.com/newsletter/Instagram: https://www.instagram.com/zachhighley/?hl=enWebsite: https://zhighley.comTwitter: https://twitter.com/zachhighleyLinkedln: https://www.linkedin.com/in/zach-highley-gergel-44763766/Business Inquiries: zachhighley@nebula.tv___Listen for FreeSpotify: https://open.spotify.com/show/23TvJdEBAJuW5WY1QHEc6A?si=cf65ae0abbaf46a4Apple Podcast: https://podcasts.apple.com/us/podcast/the-zach-highley-show/id1666374777___Welcome to the Zach Highley Show, where we discuss personal growth and medicine to figure out how to improve our lives. My name is Zach a Resident Physician in Boston. Throughout these episodes, I'll interview top performers from around the world in business, life, and medicine in hopes of extracting the resources and techniques they use to get to the top.The best way to help the show is to share episodes on any platform. If you think a friend or family member will like a certain episode, send it to them!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

EP. 259 of the I'm Always Right Sports Podcast! Check out this week's rundown and make sure to subscribe! - Michigan Sign Stealing punishment - Michigan big win over Penn State - College football playoff check in - James Harden trade - Preview of AEW Full Gear

What to expect... Penn State vs Michigan College Football Best Bets NFL Week 10 Bets Phillies Offseason Philly and the Over: email: phillyandtheover@gmail.com X: @phillyovers The stats: NFL Shane: 59% Joe: 58% NCAAF Joe: 11-8 in BigTen

Gabe Morency, Ian Cameron, and Cam Stewart have you covered with all the news you need to bet. They jump all over the place today - from College Basketball and football to NBA, NHL, and golf. First - college basketball talk, and their best bets on every game. After they jump into the college football and the headline game between Michigan and Penn State, where are they at on the total and which side do they like? Then, Cam jumps into his best golf bets and finally they wrap it up with Thursday Night Football talk and their best bets a day out from the game.

Bun gives a full breakdown of Saturday's Penn State at Ohio State matchup, including why he's dangerously optimistic about Ohio State's offense but yet preparing for a letdown and major Saturday tilt. Plus, he drops a 5-leg parlay for college football week 8.Follow Cash on Twitter: https://twitter.com/SurplusOfCashFollow Josh on Twitter: https://twitter.com/selway151Follow us on IG: https://www.instagram.com/fantasyunleashd/All things FantasyUnleashd: https://linktr.ee/FantasyUnleashdJosh's weird TikTok: https://vm.tiktok.com/TTPdhPrtSx/Beaver is on TikTok! https://vm.tiktok.com/TTPdAdF21a/

Chris Williams and Chris Hassel get you set for the upcoming weekend in college football. Iowa faces its toughest test of the season as a 14.5 point underdog at Penn State. Iowa State has another desperation game in front of it with Oklahoma State coming to town. The guys look at a loaded college football slate and make their Circa Survivor and Millions picks, all courtesy of Fareway Meat and Grocery. Learn more about your ad choices. Visit megaphone.fm/adchoices

Bun brainstorms betting angles for Big Ten games in week 3 of college football. - Virginia at Maryland- Western Kentucky at Ohio State- Minnesota at North Carolina- Washington at Michigan State - Northwestern at Duke- Penn State at Illinois (***90% of BETS on Penn State, not money***)Follow Cash on Twitter: https://twitter.com/SurplusOfCashFollow Josh on Twitter: https://twitter.com/selway151Follow us on IG: https://www.instagram.com/fantasyunleashd/All things FantasyUnleashd: https://linktr.ee/FantasyUnleashdJosh's weird TikTok: https://vm.tiktok.com/TTPdhPrtSx/Beaver is on TikTok! https://vm.tiktok.com/TTPdAdF21a/

#128: In the second half of our interview with Dr. Dave Mortensen, we hear about the events that  led to his resignation from the National Organic Standards Board, as well his thoughts around the off-base claims of "environmental consciousness" being presented today by Big Ag companies.Dave Mortensen heads the Agriculture, Nutrition, and Food Systems department at the University of New Hampshire. He was the Distinguished Professor of Weed and Applied Plant Ecology at the Penn State College of Agricultural Sciences and has also served as a farming systems ecotoxicology expert on the National Organic Standards Board.To watch a video version of this podcast please visit:https://www.realorganicproject.org/dave-mortensen-false-claims-from-big-ag-episode-one-hundred-twenty-eightThe Real Organic Podcast is hosted by Dave Chapman and Linley Dixon, engineered by Brandon StCyr, and edited and produced by Jenny Prince.The Real Organic Project is a farmer-led movement working towards certifying 1,000 farms across the United States this year. Our add-on food label distinguishes soil-grown fruits and vegetables from hydroponically-raised produce, and pasture-raised meat, milk, and eggs from products harvested from animals in horrific confinement (CAFOs - confined animal feeding operations).To find a Real Organic farm near you, please visit:https://www.realorganicproject.org/farmsWe believe that the organic standards, with their focus on soil health, biodiversity, and animal welfare were written as they should be, but that the current lack of enforcement of those standards is jeopardizing the ability for small farms who adhere to the law to stay in business. The lack of enforcement is also jeopardizing the overall health of the customers who support the organic movement; customers who are not getting what they pay for at market but still paying a premium price. And the lack of enforcement is jeopardizing the very cycles (water, air, nutrients) that Earth relies upon to provide us all with a place to live, by pushing extractive, chemical agriculture to the forefront.If you like what you hear and are feeling inspired, we would love for you to join our movement by becoming one of our 1,000  Real Friends:https://www.realorganicproject.org/real-organic-friends/To read our weekly newsletter (which might just be the most forwarded newsletter on the internet!) and get firsthand news about what's happening with organic food, farming and policy, please subscribe here:https://www.realorganicproject.org/email/